Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic…

Read More
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026. Oscar Molina | CNBC Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December….

Read More
'Devil in the details': India-U.S. deal raises hopes for a reset — but the fine print remains unclear

‘Devil in the details’: India-U.S. deal raises hopes for a reset — but the fine print remains unclear

Indian Prime Minster Narendra Modi and U.S. President Donald Trump raise clasped hands onstage at NRG Stadium during a rally on Sept. 22, 2019 in Houston, Texas. Sergio Flores | Getty Images News | Getty Images The U.S. and India announced a trade deal Monday after months of negotiations, raising hopes for a strategic reset…

Read More
Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch

Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch

Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that…

Read More
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Friday said it will spend more than $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity…

Read More